Mumps Orchitis
Post-Pubertal Mumps-Associated Orchitis and Testicular Atrophy
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (vaccine-preventable viral complication)
Reference only. Not medical advice.
What can go wrong
Acute risks are severe pain, high fever, and rarely testicular infarction. The dominant long-term risk is subfertility or infertility, especially after bilateral disease. There is no proven antiviral treatment; management is supportive, so prevention via MMR is paramount. Waning vaccine immunity and vaccine refusal drive outbreaks that put post-pubertal males at renewed risk.
This is something to take to a clinician. The Atlas can tell you what is known about mumps orchitis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Mumps orchitis is the classic post-pubertal complication of mumps virus, occurring in roughly 20-30% of infected post-pubertal males and bilateral in about 10-30% of those. It causes testicular inflammation and, in 30-50% of affected testes, subsequent atrophy. Unilateral disease rarely sterilizes, but bilateral orchitis carries a substantial infertility risk (cited across the literature as roughly 30-87% depending on series). The MMR vaccine (two doses, ~88-95% protection) has sharply reduced incidence, but outbreaks in under-vaccinated and waning-immunity populations keep it clinically relevant.
A childhood-era virus that can sterilize a grown man.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Mumps virus reaches the testis hematogenously, replicating in seminiferous tubules and triggering interstitial edema and lymphocytic infiltration. The rigid tunica albuginea limits swelling, so rising intratesticular pressure adds ischemic injury to direct viral germ-cell damage. The result is destruction of spermatogenic epithelium with relative sparing of Leydig cells, so testosterone is often preserved even when sperm production is devastated.
The catch: sterile but not hypogonadal
Because germ-cell epithelium is destroyed while Leydig cells frequently survive, a man can be azoospermic yet eugonadal after bilateral mumps orchitis - normal libido, normal testosterone, but empty ejaculate. Surgical sperm retrieval (microTESE) is sometimes successful because damage can be patchy, but atrophic testes give lower yields. The interval between the acute illness and the fertility consequence - often years - obscures the causal link.
When this is an emergency
Typically follows parotitis by 4-8 days with acute testicular pain, swelling, and fever in a post-pubertal male. Diagnosis is clinical, supported by mumps IgM/IgG serology or PCR and by ultrasound showing an enlarged, hyperemic testis. It must be distinguished from bacterial epididymo-orchitis and, urgently, from torsion.
What it does to fertility
The signature fertility disease of this list. Unilateral orchitis usually preserves fertility with, at most, mild transient decline. Bilateral orchitis with atrophy can cause severe oligozoospermia or azoospermia and is a well-documented cause of acquired infertility. Because Leydig function is typically preserved, affected men present with fertility problems rather than hypogonadal symptoms. MicroTESE may recover sperm in a subset.
What people get wrong
Often saidVaccinated men can't get mumps orchitis
ActuallyTwo MMR doses give ~88-95% protection, not 100%; breakthrough orchitis occurs during outbreaks, and waning immunity in adults is a real vulnerability.
Often saidMumps orchitis lowers testosterone
ActuallyUsually not - Leydig cells are often spared, so men can be azoospermic yet have normal testosterone and libido.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
The people taking it
Post-pubertal males during mumps outbreaks, disproportionately in under-vaccinated communities and young adults with waning immunity (e.g., college outbreaks).
What we do not know
- Do any acute-phase anti-inflammatory or antioxidant interventions preserve spermatogenesis?
- What predicts sperm-retrieval success in azoospermic mumps-orchitis survivors?
At a glance
- Orchitis in post-pubertal mumps
- ~20-30% of cases
- Bilateral
- ~10-30% of orchitis cases
- Testicular atrophy
- ~30-50% of affected testes
- Infertility after bilateral disease
- cited ~30-87% across series
- MMR protection
- ~88-95% with two doses
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Mumps Orchitis. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Davis et al., BJU International review of rising mumps orchitis incidence2010
Documents resurgence tied to outbreaks and waning immunity
Single-center series of mumps orchitis in vaccinated post-pubertal males2012
Orchitis can occur even in vaccinated men during outbreaks; characterizes clinical course
Frontiers in Immunology review, Mumps Orchitis: Clinical Aspects and Mechanisms2021
Details tubular destruction, atrophy rates, and fertility outcomes